Business
Editas Medicine Appoints Baisong Mei, M.D., Ph.D., as Chief Medical Officer
CAMBRIDGE, Mass., July 18, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the appointment of
About this update from Editas Medicine, Inc.
[{"type":"text","content":"CAMBRIDGE, Mass., July 18, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the appointment of Baisong Mei, M.D., Ph.D., as the Company’s Senior Vice President and Chief Medical Officer, effective immediately. Dr. Mei will lead clinical research and drug development for the Company’s pipeline of experimental medicines across all therapeutic indications, including hematology, oncology, and ophthalmology. “We are thrilled to have Baisong join our team. He brings to Editas a proven track record of advancing innovative medicines from IND acceptance through global regulatory approval. His extensive drug development experience and deep scientific knowledge make him an ideal partner to our research organization, enabling us to strategically advance our pipeline into and through the clinic,” said Gilmore O’Neill, M.B., M.M.Sc., President and Chief Executive Officer, Editas Medicine. “We are confident Baisong’s leadership and expertise will help us achieve our near- and long-term milestones, as we progress our scientific ideas through the drug development process and into commercialized medicines to realize our goal of providing patients with life-changing treatments.” “Editas Medicine’s blend of high-quality science, passion for developing transformative medicines, and urgency for helping patients attracted me to this role, and I am very excited to join the Editas team,” said Baisong Mei, M.D., Ph.D., Chief Medical Officer, Editas Medicine. “At Editas, we have the opportunity to make a meaningful difference in patients’ lives, as we continue to advance our innovation and development efforts and work toward achieving our goal of bringing multiple transformative medicines to market.” Dr. Mei brings to Editas more than 20 years of experience in the biotech and pharmaceutical industry, spanning the entire drug development life cycle across multiple disease areas, including hematology, neurology, and other diseases. During his career, Dr. Mei has demonstrated a strong track record in bringing novel medicines through clinical development and global regulatory approval, including Alprolix®, Eloctate®, and Onpattro®. He has led clinical development for multiple new molecular entities (protein, siRNA, gene therapy, and small molecule), from first in human to Phase 3 studies (includi...